2 Recruiting Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy Interventions: Biological: Ofatumumab; Other: No Intervention
Phase: Phase III
Primary Completion Date: November 2013

3 Recruiting Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy Interventions: Biological: Ofatumumab; Biological: Rituximab
Phase: Phase III
Primary Completion Date: November 2015

4 Recruiting Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A); Drug: Bendamustine infusion (Arm B)
Phase: Phase III
Primary Completion Date: January 2016

5 Recruiting Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia Interventions: Drug: chlorambucil, tablets; Drug: ofatumumab (GSK1841157) infusion
Phase: Phase III
Primary Completion Date: February 2013

6 Recruiting Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Interventions: Drug: Ofatumumab; Drug: Physicians' Choice
Phase: Phase III
Primary Completion Date: September 2014

7 Recruiting Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia Interventions: Drug: OFC Infusion; Drug: FC infusion
Phase: Phase III
Primary Completion Date: December 2012